Original language | English |
---|---|
Pages (from-to) | 631-633 |
Number of pages | 3 |
Journal | Infection Control and Hospital Epidemiology |
Volume | 32 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2011 |
Keywords
- immunoglobulin
- metronidazole
- vancomycin
- aged
- clinical article
- Clostridium difficile infection
- controlled study
- human
- length of stay
- letter
- male
- single drug dose
- treatment outcome
- Aged, 80 and over
- Bacterial Toxins
- Clostridium difficile
- Clostridium Infections
- Enterotoxins
- Female
- Humans
- Immunoglobulins, Intravenous
- Immunologic Factors
- Length of Stay
- Male
- Retrospective Studies
- Treatment Outcome
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections. / Aldeyab, M.A.; McElnay, J.C.; Scott, M.G.; Edwards, C.; Davies, Elizabeth ; Darwish Elhajji, F.W.; Conlon, G.; Magee, F.A.; Barr, P.J.; Kearney, M.P.
In: Infection Control and Hospital Epidemiology, Vol. 32, No. 6, 06.2011, p. 631-633.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - An evaluation of the impact of a single-dose intravenous immunoglobulin regimen in the treatment of clostridium difficile infections
AU - Aldeyab, M.A.
AU - McElnay, J.C.
AU - Scott, M.G.
AU - Edwards, C.
AU - Davies, Elizabeth
AU - Darwish Elhajji, F.W.
AU - Conlon, G.
AU - Magee, F.A.
AU - Barr, P.J.
AU - Kearney, M.P.
N1 - Cited By :7 Export Date: 15 September 2018 CODEN: ICEPE Correspondence Address: Aldeyab, M. A.; Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, BT9 7BL Belfast, Northern Ireland, United Kingdom; email: m.aldeyab@qub.ac.uk Chemicals/CAS: immunoglobulin, 9007-83-4; metronidazole, 39322-38-8, 443-48-1; vancomycin, 1404-90-6, 1404-93-9; Bacterial Toxins; Enterotoxins; Immunoglobulins, Intravenous; Immunologic Factors; tcdA protein, Clostridium difficile References: Thompson, I., Clostridium difficile-associated disease: Update and focus on non-antibiotic strategies (2008) Age Ageing, 37, pp. 14-18; McFarland, L.V., Update on the changing epidemiology of Clostridium difficile-associated disease (2008) Nat Clin Pract Gastroenterol Hepatol, 5, pp. 40-48; Kyne, L., Warny, M., Qamar, A., Kelly, C.P., Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A (2000) N Engl J Med, 342, pp. 390-397; Leffler, D.A., Lamont, J.T., Treatment of Clostridium difficile-associated disease (2009) Gastroenterology, 136, pp. 1899-1912; Gerding, D.N., Muto, C.A., Owens, R.C., Treatment of Clostridium difficile infection (2008) Clin Infect Dis, 46 (1), pp. S32-S42; Halsey, J., Current and future treatment modalities for Clostridium difficile-associated disease (2008) Am J Health Syst Pharm, 65, pp. 705-715; O'Horo, J., Safdar, N., The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review (2009) Int J Infect Dis, 13, pp. 663-667; Aldeyab, M.A., Devine, M.J., Flanagan, P., Multi-hospital outbreak of Clostridium difficile ribotype 027 infection: Epidemiology and analysis of control measures (2011) Infect Control Hosp Epidemiol, 32 (3), pp. 210-219; Tobacman, J.K., Assessment of comorbidity: A review (1994) Clin Perform Qual Health Care, 2, pp. 23-32
PY - 2011/6
Y1 - 2011/6
KW - immunoglobulin
KW - metronidazole
KW - vancomycin
KW - aged
KW - clinical article
KW - Clostridium difficile infection
KW - controlled study
KW - human
KW - length of stay
KW - letter
KW - male
KW - single drug dose
KW - treatment outcome
KW - Aged, 80 and over
KW - Bacterial Toxins
KW - Clostridium difficile
KW - Clostridium Infections
KW - Enterotoxins
KW - Female
KW - Humans
KW - Immunoglobulins, Intravenous
KW - Immunologic Factors
KW - Length of Stay
KW - Male
KW - Retrospective Studies
KW - Treatment Outcome
U2 - 10.1086/660203
DO - 10.1086/660203
M3 - Letter
VL - 32
SP - 631
EP - 633
JO - Infection Control and Hospital Epidemiology
JF - Infection Control and Hospital Epidemiology
SN - 0899-823X
IS - 6
ER -